打破恶性循环的抗血管性纳米输送系统增强和简化瘤血管正常化战略
Zhaowei Qi1, Qiongfen Yang1, Yujie Wang1
1College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
International journal of pharmaceutics
|May 30, 2025
概括
这项研究开发了新型脂质体 (ANB-SL),可以输送anlotinib以使瘤血管正常化并克服治疗挑战. ANB-SL针对与瘤相关的巨细胞,增强抗瘤免疫力,简化癌症治疗.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 瘤血管正常化策略在药物剂量和时间方面面临挑战.
- 与瘤相关的巨细胞 (TAMs) 可以干扰抗血管生成疗法.
- 目前的方法需要精确监测过渡性正常化窗口.
研究的目的:
- 开发和比较两个anlotinib (ANB) 输送系统:酸-胆固醇结合物修饰脂质体 (ANB-SL) 和多酸修饰静电复合体 (ANB-PSA).
- 评估ANB-SL在实现瘤血管正常化和增强抗瘤效果方面的有效性.
- 为了克服血管正常化疗法的临床瓶.
主要方法:
- 准备和比较ANB-SL和ANB-PSA药物递送系统.
- 评估ANB-SL对TAM和瘤丰富的向.
- 评估ANB-SL对瘤血管,免疫细胞透和瘤细胞增殖的影响.
主要成果:
- ANB-SL专门针对TAMs,导致其消除和抑制血管内皮细胞,实现瘤血管正常化.
- ANB-SL促进CD8+T细胞的透,并将瘤微环境 (TME) 转向免疫激活状态.
- ANB-SL提高了药物递送效率,并在血管正常化后发挥了抗瘤细胞毒性作用,而不依赖于精确的时间.
结论:
- 通过向TAMs,ANB-SL有效地使瘤血管正常化,并增强抗瘤免疫力.
- 这种新型的输送系统简化了瘤血管正常化策略,为癌症治疗提供了有效的方法.
- 通过将血管正常化与直接抗瘤作用相结合,ANB-SL提供了新的治疗见解.
更多相关视频
09:01Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
11.1K
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
9.7K
相关概念视频
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
